OTTAWA, ON, May 11, 2021 /CNW/ - Farm Boy Company Inc. is recalling Farm Boy The Bake Shop brand Tres Leches Cake from the marketplace because it contains wheat which is not declared on the label. People who have an allergy to wheat, or have celiac disease or other gluten-related disorders should not consume the recalled product described below.
The following product has been sold in Ontario.
Recalled product
Brand
Product
Size
UPC
Codes
Farm Boy
The Bake Shop
Tres Leches Cake
450 g
8 08912 02284 0
Best Before:
MA12
What you should do
Check to see if you have the recalled product in your home. Recalled products should be thrown out or returned to the store where they were purchased.
If you have an allergy to wheat, or have celiac disease or other gluten-related disorders, do not consume the recalled product as it may cause a serious or life-threatening reaction.
This recall was triggered by the company. The Canadian Food Inspection Agency (CFIA) is conducting a food safety investigation, which may lead to the recall of other products. If other high-risk products are recalled, the CFIA will notify the public through updated Food Recall Warnings.
The CFIA is verifying that industry is removing the recalled product from the marketplace.
Reactions
There have been no reported reactions associated with the consumption of this product.
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology...
The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that the firm has filed a securities fraud class action lawsuit against agilon health, inc. ("agilon" or the "Company"). This action, captioned Hope v. agilon health, inc., et...
bioLytical Laboratories Inc. announced today the immediate availability of its INSTI® HCV Antibody Test in the Australian market. The INSTI Hepatitis C (HCV) Antibody Test is now included in the Australian Register of Therapeutic Goods (ARTG...
The Phase IIa COURSE trial was a proof-of-concept study in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of blood eosinophil counts (BEC) and irrespective of emphysema, chronic bronchitis or...
Endeavor BioMedicines, a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, announced results from a completed Phase 2a clinical trial...
Savara Inc. (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the American Thoracic Society (ATS) 2024 International Conference that is taking place May 17-22, 2024, in San Diego,...